Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. As weight‑loss drugs…
Modular Medical’s (NASDAQ: MODD) latest regulatory milestone upgrades the narrative: the company has now secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, moving from “launch‑ready” to “launch‑approved” in the heart of the fast‑growing diabesity market.
Pivot Patch Pump Gets…
The global “diabesity” market is swelling into a once‑in‑a‑generation opportunity, and Eli Lilly, Novo Nordisk—and now a new class of device innovators like Modular Medical (NASDAQ: MODD)—are still lacing up their running shoes rather than sprinting for the finish line. For investors,…
MiniMed’s (MMED) IPO, Modular Medical’s (MODD) financing sprint, and Insulet’s (PODD) new data readout together sketch a surprisingly upbeat picture for diabetes tech investors watching the next leg of insulin-delivery innovation.
Diabetes Tech Steps Into the Spotlight
In early March, MiniMed Group,…
Tandem Diabetes Care’s (TNDM) latest trip to the capital markets reads less like a distress signal and more like a company quietly extending its runway in a race it fully intends to finish. At the same time, a familiar name in diabetes…
McDonald’s (MCD) has handled low-carb fads, kale revolutions, and the brief reign of cauliflower rice, but its newest rival comes with a prescription label and a co-pay. GLP-1 weight-loss medicines—from injectables like Eli Lilly’s (LLY) Mounjaro and Zepbound to the next wave…
Modular Medical’s (NASDAQ: MODD) Pivot insulin delivery system is quietly building a credible bull case that now extends beyond regulatory momentum and leadership credentials into hard operational execution. With the company achieving a key manufacturing milestone for its Pivot tubeless insulin patch…